GSK plc GLAXF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.70% | 5.82% | 8.58% | 10.26% | 10.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.70% | 5.82% | 8.58% | 10.26% | 10.54% |
| Cost of Revenue | -0.22% | -3.82% | 4.03% | 7.12% | -0.34% |
| Gross Profit | 5.09% | 9.40% | 10.15% | 11.69% | 14.99% |
| SG&A Expenses | 0.29% | 3.37% | 8.59% | 5.63% | -40.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 87.98% | 16.66% | -284.72% | -475.59% | 23.51% |
| Total Operating Expenses | 7.70% | 4.32% | -0.12% | 2.00% | -17.68% |
| Operating Income | -4.90% | 9.32% | 28.18% | 68.87% | 321.31% |
| Income Before Tax | -21.42% | -81.15% | 8.80% | 75.24% | 3,876.38% |
| Income Tax Expenses | -25.84% | -182.98% | -2.90% | 273.53% | 32,429.43% |
| Earnings from Continuing Operations | -20.78% | -66.24% | 11.02% | 50.70% | 3,317.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -21.81% | 41.59% | 26.28% | -8.62% | -10.36% |
| Net Income | -23.55% | -69.71% | 14.41% | 59.54% | 3,696.29% |
| EBIT | -4.90% | 9.32% | 28.18% | 68.87% | 321.31% |
| EBITDA | -0.59% | -5.71% | 10.32% | 51.03% | 113.77% |
| EPS Basic | -23.08% | -69.33% | 16.27% | 62.05% | 3,737.30% |
| Normalized Basic EPS | -9.31% | 20.44% | 35.84% | 94.23% | 616.23% |
| EPS Diluted | -23.02% | -69.38% | 15.94% | 60.64% | 3,678.92% |
| Normalized Diluted EPS | -9.22% | 20.37% | 35.76% | 94.07% | 614.71% |
| Average Basic Shares Outstanding | -0.62% | -1.21% | -1.59% | -1.52% | -1.13% |
| Average Diluted Shares Outstanding | -0.71% | -1.17% | -1.52% | -1.42% | -0.94% |
| Dividend Per Share | 5.98% | 6.79% | 13.65% | 16.84% | 10.50% |
| Payout Ratio | 0.37% | 2.68% | -0.02% | -0.31% | 1.03% |